

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**75-232**

**APPROVAL LETTER**

JAN 6 2000

L. Perrigo Company  
Attention: Brian R. Schuster  
117 Water Street  
Allegan, MI 49010

Dear Sir:

This is in reference to your abbreviated new drug application dated February 23, 1998, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act (Act), for Loperamide Hydrochloride Tablets USP, 2 mg (Caplets).

Reference is also made to your amendments dated July 9, 1998; and September 23, November 18, and December 30, 1999.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted over-the-counter (OTC) labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Loperamide Hydrochloride Tablets USP, 2 mg (Caplets) to be bioequivalent and, therefore, therapeutically equivalent to the listed drug, Imodium A-D Caplets (reformulated smaller caplet) of McNeil Consumer Products Company). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under section 506A of the Act, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Sincerely yours,

*D. L. Sporn 1/6/99*

Douglas L. Sporn  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research